Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 6/20 | 0.38 |
| ▸ | TYMP | P19971 | 4/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28118933 | 0.98 | JAK2 (0.55) | JAK2THRBLIPGKDM4EALDH1A1 | |
| SCHEMBL5209445 | 0.82 | JAK2 (0.42) | JAK2THRBLIPGKDM4EALDH1A1 | |
| SCHEMBL122310 | 0.77 | JAK2 (0.57) | JAK2THRBDHODHTYMP | |
| SCHEMBL21996611 | 0.77 | GDA (0.43) | JAK2THRBLIPGKDM4EALDH1A1 | |
| SCHEMBL22783664 | 0.77 | JAK2 (0.61) | JAK2THRBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18704204 | 0.76 | JAK2 (0.50) | JAK2THRBALDH1A1TDP1DHODH | |
| Hydrochloric Acid SCHEMBL11433334 | 0.76 | JAK2 (0.55) | JAK2THRBDHODHTYMP | |
| SCHEMBL16543119 | 0.75 | LIPG (0.46) | JAK2THRBLIPGKDM4EALDH1A1 | |
| SCHEMBL31330663 | 0.75 | KDM4C (0.51) | JAK2THRBLIPGKDM4EALDH1A1 | |
| SCHEMBL25391975 | 0.74 | JAK2 (0.59) | JAK2THRBLIPGALDH1A1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| EP-4551575-A2 | TREM2 MODULATORS | Muna Therapeutics ApS (DK) | 2025-05-14 | — | — | EP | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| CN-119403806-A | TREM2 modulators | 穆纳治疗有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-117518321-A | Multilayer film reflector and preparation method thereof | 中国科学院上海光学精密机械研究所 | 2024-02-06 | — | — | CN | claimed |
| WO-2024008722-A2 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2024-01-11 | — | — | WO | claimed |
| CN-116639822-A | Composition for preparing scale inhibitor, preparation method and application of scale inhibitor | 山东诺尔生物科技有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-115260091-A | Ceramide compound containing cyclic carboxylic acid and preparation method and application thereof | 深圳市迪克曼生物科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| US-20040202825-A1 | RECORDING SHEETS CONTAINING PURINE, PYRIMIDINE, BENZIMIDAZOLE, IMIDAZOLIDINE, URAZOLE, PYRAZOLE, TRIAZOLE, BENZOTRIAZOLE, TETRAZOLE, AND PYRAZINE COMPOUNDS | XEROX CORPORATION | 2004-10-14 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673783-B1 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORP (US) | 2000-07-05 | — | — | EP | claimed |
| US-5659348-A | APPLYING TO A SUBSTRATE | XEROX CORPORATION (US) | 1997-08-19 | — | — | US | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |